RT Journal Article
SR Electronic
T1 Increased frequency of repeat expansion mutations across different populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.03.23292162
DO 10.1101/2023.07.03.23292162
A1 Ibañez, Kristina
A1 Jadhav, Bharati
A1 Zanovello, Matteo
A1 Gagliardi, Delia
A1 Clarkson, Christopher
A1 Facchini, Stefano
A1 Garg, Paras
A1 Martin-Trujillo, Alejandro
A1 Gies, Scott J
A1 Deforie, Valentina Galassi
A1 Dalmia, Anupriya
A1 Moss, Davina J. Hensman
A1 Vandrovcova, Jana
A1 Rocca, Clarissa
A1 Moutsianas, Loukas
A1 Marini-Bettolo, Chiara
A1 Walker, Helen
A1 Turner, Chris
A1 Shoai, Maryam
A1 Long, Jeffrey D
A1 ,
A1 Fratta, Pietro
A1 Langbehn, Douglas R
A1 Tabrizi, Sarah J
A1 Caulfield, Mark J
A1 Cortese, Andrea
A1 Escott-Price, Valentina
A1 Hardy, John
A1 Houlden, Henry
A1 Sharp, Andrew J
A1 Tucci, Arianna
YR 2024
UL http://medrxiv.org/content/early/2024/07/08/2023.07.03.23292162.abstract
AB Repeat expansion disorders (REDs) are a devastating group of predominantly neurological diseases. Together they are common, affecting 1 in 3,000 people worldwide with population-specific differences. However, prevalence estimates of REDs are hampered by heterogeneous clinical presentation, variable geographic distributions, and technological limitations leading to under-ascertainment. Here, leveraging whole genome sequencing data from 82,176 individuals from different populations, we found an overall disease allele frequency of REDs of 1 in 283 individuals. Modelling disease prevalence using genetic data, age at onset and survival, we show that the expected number of people with REDs would be two to three times higher than currently reported figures, indicating under-diagnosis and/or incomplete penetrance. While some REDs are population-specific, e.g. Huntington disease-like 2 in Africans, most REDs are represented in all broad genetic ancestries (i.e. Europeans, Africans, Americans, East Asians, and South Asians), challenging the notion that some REDs are found only in specific populations. These results have worldwide implications for local and global health communities in the diagnosis and counselling of REDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by and funding from the UKRI (Medical Research Council Clinician Scientist award, MR/S006753/1) to A.T. and Barts charity (MGU0569). A.J.S. received support from NIH grants AG075051, NS105781, HD103782 and NS120241, and A.M.T. received support from NHLBI Biodata Catalyst fellowship 5120339.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Genomics England Research Environment and TopMedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes